je.st
news
Merck challenges Gilead with $3.85B hepatitis C acquisition
2014-06-10 05:02:20| Biotech - Topix.net
Merck will spend about $3.85 billion for Idenix Pharmaceuticals, a small company developing hepatitis C medicines that, together with Merck's experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions.
Tags: challenges
acquisition
hepatitis
merck
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||